Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
34.09
+0.31 (+0.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Analyst Expectations For Celldex Therapeutics's Future
↗
April 28, 2025
Via
Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
April 28, 2025
Via
Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
↗
March 20, 2025
Via
Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
March 20, 2025
Via
Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 04, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
↗
February 28, 2025
Via
Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
↗
January 29, 2025
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
↗
December 20, 2024
Via
Benzinga
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 03, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 27, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
↗
November 20, 2024
Via
Benzinga
Analyst Expectations For Celldex Therapeutics's Future
↗
October 28, 2024
Via
Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
↗
September 25, 2024
Via
Benzinga
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
↗
September 09, 2024
Via
Benzinga
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
February 18, 2025
Via
Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
↗
January 08, 2025
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Via
Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 19, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 20, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
7 Analysts Have This To Say About Celldex Therapeutics
↗
August 12, 2024
Via
Benzinga
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
September 27, 2024
Via
Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 09, 2024
CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
July 30, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
